Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma

Autor: Ilse van Engen-van Grunsven, Gerald W. Verhaegh, Stefan M. Willems, Wim van Boxtel, Maike J. M. Uijen, Jack A. Schalken, Marianne A. Jonker, Carla M.L. van Herpen
Přispěvatelé: Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Rok vydání: 2020
Předmět:
Oncology
Male
Cancer Research
HEPATOCYTE GROWTH-FACTOR
Gene Expression
Kaplan-Meier Estimate
Proto-Oncogene Mas
Salivary duct carcinoma
Androgen
chemistry.chemical_compound
0302 clinical medicine
MEMBRANE ANTIGEN-EXPRESSION
ADENOID CYSTIC CARCINOMA
Receptors
VASCULATURE
Neoplasm Metastasis
030223 otorhinolaryngology
Lymph node
In Situ Hybridization
Aged
80 and over
OUTCOMES
Tissue microarray
Hazard ratio
Middle Aged
Proto-Oncogene Proteins c-met
Cadherins
Prognosis
Salivary Gland Neoplasms
Immunohistochemistry
Women's cancers Radboud Institute for Health Sciences [Radboudumc 17]
Carcinoma
Ductal
medicine.anatomical_structure
Receptors
Androgen
030220 oncology & carcinogenesis
SURVIVAL
Female
Disease Susceptibility
Oral Surgery
Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Adult
medicine.medical_specialty
Proteasome Endopeptidase Complex
C-Met
BREAST
03 medical and health sciences
All institutes and research themes of the Radboud University Medical Center
Internal medicine
Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]
medicine
PSMA
Biomarkers
Tumor
Humans
Survival analysis
SCATTER FACTOR
erbB-2
Aged
Neoplasm Staging
Proportional Hazards Models
business.industry
Proportional hazards model
E-cadherin
Genes
erbB-2
medicine.disease
chemistry
Genes
Salivary gland cancer
HER-2
ANDROGEN DEPRIVATION THERAPY
business
Zdroj: Oral Oncology, 110:105018. ELSEVIER SCIENCE BV
Oral Oncology, 110
ISSN: 1879-0593
1368-8375
Popis: Objectives: Salivary duct carcinoma (SDC) is a rare and aggressive subtype of salivary gland cancer. Androgen receptor (AR) (96%) and HER2 (29-46%) expression, and a high propensity for regional lymph node metastases are hallmarks of the disease. We hypothesized that c-MET, E-cadherin, PSMA tumor and PSMA neovascular expression may be prognostic factors in SDC.Materials and methods: Expression levels of these proteins were established on tissue microarrays containing 165 primary SDC tumor specimens. Association with survival was studied with Kaplan-Meier curves, and univariable and multivariable Cox regression models. Furthermore, association with lymph node status, AR and HER2 expression, and gender was studied.Results: We found that patients with high PSMA tumor expression showed a significantly longer overall survival (OS) (median 83 vs. 43 months, P = 0.022), a trend towards a longer DFS (median 51 vs. 22 months, P = 0.094), and significantly reduced hazard ratio for death in the univariable Cox regression model (HR 0.46, P = 0.034). In the multivariable model only a high number of tumor-positive lymph nodes and high age (> 80) at diagnosis were prognostic for poor OS. High PSMA tumor expression was also significantly associated with low N-stage (P = 0.001) and expression was higher in women versus men (P = 0.029). High PSMA tumor expression and Ecadherin loss were significantly associated with strong and weak AR-expression, respectively (P = 0.033 and P = 0.007). None of the factors were significantly associated with HER2 expression.Conclusion: c-MET, E-cadherin, and tumor and neovascular PSMA expression are no independent prognostic factors in SDC.
Databáze: OpenAIRE
Externí odkaz: